Globus Medical Inc. (NYSE:GMED), a leading medical device company specializing in musculoskeletal disorders, has been making waves in the healthcare sector with its recent acquisition of Nevro Corp ...

Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...

Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the ...

StockNews.com upgraded shares of Globus Medical (NYSE:GMED – Free Report) from a hold rating to a buy rating in a research ...

State of Alaska Department of Revenue reduced its stake in shares of Globus Medical, Inc. (NYSE:GMED – Free Report) by 1.2% ...

Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical ...

The CEO of Globus Medical said the deal will enable the Audubon company to expand into new markets for future growth.

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Globus Medical (GMED) reports results for the quarter ended December 2024. While this widely-known consensus ...